Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Patients With Thrombocytopenia Following HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Platelet count ≤ 30 × 109/L persistently at day 60 post-HSCT or later;~2. Neutrophil and hemoglobin were well recovered;~3. Full donor chimerism was achieved;~4. No response to conventional treatments (e.g. thrombopoietin, immunoglobulin, glucocorticoid alone or in combination) for a duration of at least 4 weeks;~Exclusion Criteria:~1. Patients with malignancy relapse;~2. Active infections;~3. Grade Ⅲ-Ⅳ acute GVHD or severe chronic GVHD according to National Institute of Health criteria;~4. Severe organ damage;~5. Thrombosis requiring treatment;~6. Received decitabine following the current transplantation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Group 1 (Type: EXPERIMENTAL): Decitabine in combination with rhTPO.
- Experimental Group 2 (Type: EXPERIMENTAL): Decitabine
- Control Group (Type: ACTIVE_COMPARATOR): Conventional treatment except decitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).